Ticagrelor Pregnancy and Breastfeeding Warnings

Brand names: Brilinta

Medically reviewed by Drugs.com. Last updated on Jan 13, 2025.

Ticagrelor Pregnancy Warnings

AU and UK: Use is not recommended.
US: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

AU TGA pregnancy category: B1
US FDA pregnancy category: C

Comments: Use of adequate methods of contraception should be encouraged.

Animal studies have revealed structural abnormalities, reproductive toxicity, and fetolethality. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Ticagrelor Breastfeeding Warnings

Use is not recommended; a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer